- Home
- CCIX vs AURA Comparison
CCIX vs AURA Comparison
Compare CCIX & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
HOLD
Current Price
$6.34
Company Overview
Basic Information| Metric | CCIX | AURA |
|---|---|---|
| Founded | 2023 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 390.8M | 396.8M |
| IPO Year | 2024 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CCIX | AURA |
|---|---|---|
| Price | $10.57 | $6.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $20.33 |
| AVG Volume (30 Days) | 98.1K | ★ 189.7K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.25 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $42.41 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.21 | $4.35 |
| 52 Week High | $11.66 | $9.14 |
Technical Indicators
Market Signals| Indicator | CCIX | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 35.42 | 58.33 |
| Support Level | $10.61 | $6.27 |
| Resistance Level | $10.64 | $6.55 |
| Average True Range (ATR) | 0.02 | 0.31 |
| MACD | -0.00 | 0.06 |
| Stochastic Oscillator | 0.00 | 79.35 |
Price Performance
Historical Comparison CCIX
AURA
About CCIX Churchill Capital Corp IX Ordinary Shares
Churchill Capital Corp IX is a blank check company.
About AURA Aura Biosciences Inc.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.